Environment International (Jan 2019)
Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study
- Paula Peremiquel-Trillas,
- Yolanda Benavente,
- Mayte Martín-Bustamante,
- Delphine Casabonne,
- Beatriz Pérez-Gómez,
- Inés Gómez-Acebo,
- Anna Oliete-Canela,
- Marta Diéguez-Rodríguez,
- Ignasi Tusquets,
- Pilar Amiano,
- Lourdes Mengual,
- Eva Ardanaz,
- Rocío Capelo,
- Antonio J. Molina de la Torre,
- Dolores Salas Trejo,
- Guillermo Fernández-Tardón,
- Virginia Lope,
- José J. Jimenez-Moleon,
- Rafael Marcos-Gragera,
- Trinidad Dierssen-Sotos,
- Mikel Azpiri,
- Montse Muñoz,
- Marcela Guevara,
- Tania Fernández-Villa,
- Ana Molina-Barceló,
- Nuria Aragonés,
- Marina Pollán,
- Gemma Castaño-Vinyals,
- Juan Alguacil,
- Manolis Kogevinas,
- Silvia de Sanjosé,
- Laura Costas
Affiliations
- Paula Peremiquel-Trillas
- Preventive Medicine and Epidemiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
- Yolanda Benavente
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain
- Mayte Martín-Bustamante
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
- Delphine Casabonne
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain
- Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; Cardiovascular & Metabolic Diseases Unit, National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
- Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Universidad de Cantabria – IDIVAL, Santander, Spain
- Anna Oliete-Canela
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
- Marta Diéguez-Rodríguez
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
- Ignasi Tusquets
- Universitat Autònoma de Barcelona, Parc de Salut Mar Hospital del Mar, Barcelona, Spain; Medical Oncology Department, Parc de Salut Mar Hospital del Mar, Barcelona, Spain
- Pilar Amiano
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
- Lourdes Mengual
- Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
- Eva Ardanaz
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain
- Rocío Capelo
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente, Universidad de Huelva, Huelva, Spain
- Antonio J. Molina de la Torre
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
- Dolores Salas Trejo
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Cancer and Public Health Area, FISABIO – Public Health, Valencia, Spain; General Directorate Public Health, Valencian Community, Valencia, Spain
- Guillermo Fernández-Tardón
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Instituto de Oncología de Asturias (IUOPA), Área de Medicina Preventiva, Universidad de Oviedo, Oviedo, Spain
- Virginia Lope
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
- José J. Jimenez-Moleon
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, University of Granada, Granada, Spain
- Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona, Spain; Girona Biomedical Research Institute (IDIBGI), University of Girona, Girona, Spain
- Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Universidad de Cantabria – IDIVAL, Santander, Spain
- Mikel Azpiri
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
- Montse Muñoz
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Clínic de Barcelona, Barcelona, Spain
- Marcela Guevara
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain
- Tania Fernández-Villa
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
- Ana Molina-Barceló
- Cancer and Public Health Area, FISABIO – Public Health, Valencia, Spain
- Nuria Aragonés
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
- Marina Pollán
- CIBER Epidemiología y Salud Pública – CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
- Gemma Castaño-Vinyals
- ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute – IMIM, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Juan Alguacil
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente, Universidad de Huelva, Huelva, Spain
- Manolis Kogevinas
- ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute – IMIM, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; National School of Public Health, Athens, Greece
- Silvia de Sanjosé
- PATH, Seattle, USA
- Laura Costas
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Corresponding author at: Unit of Molecular Epidemiology and Genetics in Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d'Oncologia, Av. Gran Via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Spain.
- Journal volume & issue
-
Vol. 122
pp. 389 – 399
Abstract
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case–control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01–1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02–1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00–1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies. Keywords: Alkylphenols, Alkylphenolic compounds, Job-exposure matrix, Breast cancer, Prostate cancer, Occupational exposure